Liquidia (NASDAQ:LQDA) Shares Up 4.3%

Liquidia Co. (NASDAQ:LQDA - Get Free Report)'s stock price rose 4.3% during trading on Monday . The stock traded as high as $13.64 and last traded at $13.49. Approximately 180,271 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 870,490 shares. The stock had previously closed at $12.94.

Analyst Ratings Changes

LQDA has been the topic of several analyst reports. HC Wainwright restated a "buy" rating and issued a $32.00 price target on shares of Liquidia in a research note on Wednesday, May 15th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 price objective on shares of Liquidia in a report on Monday, June 3rd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Liquidia has a consensus rating of "Moderate Buy" and an average target price of $21.00.

Liquidia Price Performance

The firm's fifty day moving average price is $13.20 and its 200-day moving average price is $12.92. The firm has a market capitalization of $1.02 billion, a P/E ratio of -8.63 and a beta of 0.25.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Monday, May 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.22). The business had revenue of $2.97 million for the quarter, compared to the consensus estimate of $4.31 million. Liquidia had a negative return on equity of 177.83% and a negative net margin of 674.42%. Analysts expect that Liquidia Co. will post -1.26 earnings per share for the current year.

Insider Buying and Selling

In related news, General Counsel Russell Schundler sold 2,060 shares of the firm's stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $30,034.80. Following the completion of the sale, the general counsel now directly owns 486,027 shares in the company, valued at $7,086,273.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO Michael Kaseta sold 3,136 shares of the company's stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total value of $45,722.88. Following the completion of the sale, the chief financial officer now owns 315,045 shares in the company, valued at approximately $4,593,356.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel Russell Schundler sold 2,060 shares of the company's stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $14.58, for a total transaction of $30,034.80. Following the completion of the sale, the general counsel now owns 486,027 shares of the company's stock, valued at approximately $7,086,273.66. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 18,653 shares of company stock worth $270,409. Corporate insiders own 31.60% of the company's stock.

Institutional Investors Weigh In On Liquidia

Several hedge funds have recently made changes to their positions in LQDA. Fortitude Family Office LLC purchased a new stake in shares of Liquidia in the 4th quarter valued at approximately $26,000. Aigen Investment Management LP purchased a new stake in shares of Liquidia in the 3rd quarter valued at approximately $80,000. Tower Research Capital LLC TRC lifted its position in shares of Liquidia by 610.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,997 shares of the company's stock valued at $108,000 after acquiring an additional 7,731 shares in the last quarter. Corton Capital Inc. lifted its position in shares of Liquidia by 14.2% in the 3rd quarter. Corton Capital Inc. now owns 23,440 shares of the company's stock valued at $149,000 after acquiring an additional 2,921 shares in the last quarter. Finally, Greenleaf Trust purchased a new stake in Liquidia in the 4th quarter worth approximately $164,000. Hedge funds and other institutional investors own 64.54% of the company's stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).